(i) Most commonly prescribed DMT in the USA [8, 9]
 (ii) Administered in clinical practice for over 20 years; over 2 million patient-years of exposure [60]
 (iii) Dosing options of 20 mg daily or 40 mg three-times weekly via subcutaneous injection
 (iv) Associated with a favorable rate of patient adherence [123, 124]
    (a) Good patient acceptance of route of administration; support available from Shared Solutions® program
 (i) GA 20 mg daily associated with 35% reduction in ARR, 22% reduction in disability progression
 (network meta-analysis [125]), and decreased brain-lesion activity, compared with placebo
 (ii) Few head-to-head studies with other DMTs in relapsing-remitting MS
    (a) Similar efficacy to IFN betas in head-to-head studies for clinical (relapse, confirmed progression) and MRI activity
      measures, although IFN beta treatments were found to limit the increase in lesion burden to a greater extent
      than GA [68]
    (b) Evidence (from network meta-analysis) of greater efficacy for alemtuzumab, mitoxantrone, and natalizumab
      compared with GA in reducing ARR and for alemtuzumab with regard to disability worsening [105]
 (iii) Data are not yet available from randomized controlled studies that investigate switching from other DMTs to GA
 (i) Injection-site reactions were the most common adverse events reported in clinical trials (49% of patients; predominantly
 erythema and pain) [60]
    (a) Other common adverse events were rash (15%), headache (14%), infection (12%), dyspnea (12%), and vasodilation (11%)
 (ii) No monitoring requirement
 (iii) Pregnancy category B label in the USA; pregnancy contraindication removed from the EU label in December 2016
 (iv) No deaths associated with treatment in 20 clinical trials [60]
 (v) No evidence of immunosuppression, autoimmune disease, or development of neutralizing antibodies [37, 60]
 (vi) Postmarketing surveillance has not revealed risk for opportunistic infections (including PML) [60]
Box 1: Summary of characteristics of branded glatiramer acetate in MS. ARR: annualized relapse rate; DMT: disease-modifying treatment; GA, branded glatiramer acetate; IFN: interferon; MS: multiple sclerosis; PML: progressive multifocal leukoencephalopathy.